期刊文献+

皂角刺提取物对荷瘤小鼠肿瘤生长及细胞因子的影响 被引量:9

Effects of Extractive from Spina Gleditsiae (ESG)on Tumor Growth and Cytokines in Tumor-bearing Mice
下载PDF
导出
摘要 目的探讨皂角刺提取物对荷瘤小鼠肿瘤生长及细胞因子水平的影响。方法建立小鼠肉瘤S180及小鼠肝癌H22移植性肿瘤模型,观察皂角刺提取物对荷瘤小鼠肿瘤生长的抑制作用;采用ELISA法测定白介素-2(IL-2)、白介素-6(IL-6)、白介素-12(IL-12)、肿瘤坏死因子-α(TNF-α)的水平,探讨皂角刺提取物对荷瘤小鼠细胞因子的影响。结果皂角刺提取物在50、100mg/kg时对S180的生长抑制率分别为44.59%、53.38%,对H22生长抑制率分别为39.88%、46.63%,且能提高荷瘤小鼠的脾指数和胸腺指数;皂角刺提取物能提高荷瘤小鼠细胞因子IL-2、IL-6、IL-12、TNF-α的表达水平。结论皂角刺提取物有较强的体内抗肿瘤活性,且能促进细胞因子的表达,增强机体免疫功能。 Objective To study the effects of Extractive from Spina Gleditsiae (ESG)on the tumor growth and cytokines in tumor-bearing mice. Methods Antitumor activity of ESG in vivo was observed by the models of implanted H22 or S180 cell line in mice. The expression of TNF-α. IL2,IL-6 and IL-12 in tumor-bearing mice was detected by ELISA assay. Results At dosage of 50. 100 mg·kg^-1, inhibitory rate of ESG is 44. 59% and 53.38% for S180, 39. 88% and 46. 63% for H22, respectively. ESG can increase the expression of TNF-α.IL-2.IL-6 and IL-12. Conclusion ESG exhibits anti-tumor effect obviously in vivo and enhances immune function by promoting the expression of cytokine.
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2009年第5期365-367,共3页 Cancer Research on Prevention and Treatment
基金 四川省教育厅重点资助项目(2005A065)
关键词 皂角刺提取物 荷瘤小鼠 细胞因子 ELISA Extractive from Spina Gleditsiae Tumor-bearing mice Cytokine ELISA
  • 相关文献

参考文献7

二级参考文献56

  • 1Chow L M, Tang J C, Teo I T, et al. Antiproliferative activity of the extract of Gleditsia sinensis fruit on human solid tumour cell lines.Chemotherapy, 21302, 48(6): 303.
  • 2Chow L M, Chui C H, Tang J C, et al, Gleditsia sinensis fruit extract is a potential chemotherapeutic agent in chronic and acute myelogenous leukemia. Oncol Rep, 2003, 10 (5): 1601.
  • 3吴达 梁冰 师彦平.甘肃棘豆生物碱对荷S180肉瘤小鼠PCNA,p53蛋白表达的干预作用[J].中华现代医药杂志,2003,(1):1-1.
  • 4[1]Mark DS, Werb Z. ECM proteinases [A]. Thomas K,Ronal V. Guidebook to the extracellular matrix, anchor, and anhesion proteins [M]. ed 2. New York: Oxford University Press Inc, 1999.505-509.
  • 5[2]Sternlicht MD, Coussens LM, Vu TH, et al. Biology and regulation of the matrix metalloproteinases [A]. Clendeninn NJ, Appelt K. Matrix metalloproteinase inhibitors in cancer therapy [M]. Totowa: Humana Press Inc, 2001.1-37.
  • 6[3]Cox G, O'byrne KJ. Matrix metalloproteinase and cencer [J]. Anticancer Res, 2001,21(6B):4207-4219.
  • 7[4]O-charoenrat P, Modjtahedi H, Rhys-Evans P. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells [J]. Cancer Res, 2000,60(4):1121-1128.
  • 8[5]Cox G, Jones JL,O'Byrne KJ. MMP-9 and the epidermal growth factor receptor signal pathway in operable non-small cell lung cancer [J]. Clin Cancer Res, 2000,6(6):2349-2355.
  • 9[6]Westermarck J,Kahari VM.Regulation of matrix met-salloproteinase expression in tumor invasion [J]. FASEB J, 1999,13(8):781-792.
  • 10[7]Leevers SJ, Vanhaesebroeck B, Waterfield MD. Signalling through phosphoinositide 3-kinases: the lipids take centre stage [J]. Curr Opin Cell Biol, 1999,11(2):219-225.

共引文献47

同被引文献138

引证文献9

二级引证文献139

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部